Innova CaptabBOM:544067 -1.82%46 EBITDA Margin % is 14.89% as of Mar. 2026, which is 3% above its 10-year median of 14.52. GuruFocus rates BOM:544067 with a GF Score™ of 46/100. The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Innova Captab ranks better than 57.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Innova Captab's EBITDA for the
three
months ended in Mar. 2026 was ₹667 Mil. Innova Captab's Revenue for the
three
months ended in Mar. 2026 was ₹4,478 Mil. Therefore, Innova Captab's EBITDA margin for the quarter that ended in Mar. 2026 was 14.89%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Innova Captab EBITDA Margin % Related Terms
Innova Captab EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Innova Captab's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544067 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innova Captab EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Innova Captab's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Innova Captab's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innova Captab (BOM:544067) has a EBITDA Margin % of 14.89% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Innova Captab and its competitors. This is near median its historical median of 14.52. Over the past decade, Innova Captab's EBITDA Margin % has ranged from 12.32 to 16.04. According to the industry distribution chart, Innova Captab ranks #407 out of 952 companies in the Drug Manufacturers industry, placing it in the top 42.8%.
Is Innova Captab's EBITDA Margin % too high?
Innova Captab's current EBITDA Margin % of 14.89% is near median its 10-year median of 14.52. Over the past 10 years, this metric has ranged from a low of 12.32 to a high of 16.04. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Innova Captab's value of 14.89% is 19.4% above this industry median. Based on the distribution chart, Innova Captab ranks #407 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Innova Captab has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Innova Captab ranks #407 out of 952 companies for EBITDA Margin %. This puts Innova Captab in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Innova Captab's value of 14.89% is 19.4% above this benchmark. Historically, Innova Captab's own EBITDA Margin % has ranged from 12.32 to 16.04 over the past decade. While the company's 10-year median is 14.52 vs. the industry median of 12.47, Innova Captab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innova Captab's current EBITDA Margin % of 14.89% is 19.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Innova Captab and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innova Captab's current EBITDA Margin % is 14.89%, which is near median its own 10-year median of 14.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Innova Captab (BOM:544067) has a current EBITDA Margin % of 14.89%. The current EBITDA Margin % is 14.89%, which is near median its 10-year median of 14.52 and 19.4% above the Drug Manufacturers industry median of 12.47. Innova Captab's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Innova Captab (BOM:544067), the current EBITDA Margin % is 14.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
46GF Score
Get the complete analysis for BOM:544067
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544067 has been successfully added to your 
